Improving the viral plaque assay speed, sensitivity and robustness using imaging cytometry
Improved fluorescent plaque assay method using fluorescently-labeled antibodies and the use of the Celigo image cytometer.
22nd Annual Merck Technology Symposium
Come visit us at booth #413 Merck Technology Symposium 2018 September 5-6, 2018 Ocean Place Resort Long Branch, NJ Posters being presented: High-throughput foci counting of viral titer and antibody neutralization assays using the Celigo Image Cytometer for developing a novel cross-reactive influenza vaccine Long-term time-course monitoring of NK cell-mediated ADCC using the Celigo Image Cytometer A high-throughput 3D tumor spheroid screening method for drug discovery using imaging cytometry
-
Automated Cell Counters: Accurate, Reproducible Cell Counts for the Entire Cell Therapy Workflow GalleryAutomated Cell Counters: Accurate, Reproducible Cell Counts for the Entire Cell Therapy Workflow
Bioprocessing/Cell Live Development, CAR T / Cell Therapy, Celigo, Celigo Application News, Cellometer, Cellometer Application News, Instrument, Latest News
Automated Cell Counters: Accurate, Reproducible Cell Counts for the Entire Cell Therapy Workflow
Cellometer automated cell counters have been facilitating CAR T manufacturing with accurate cell counting and analysis since 2010.
Celigo Provides Image-Based Proof of Single-Cell Clonality
The FDA identifies clonality as one of the most crucial steps in guaranteeing cell line quality and safety. The Celigo Image Cytometer makes single cell sorting easy.
Celigo furthers studies of homologous recombination DNA repair machinery
The Danish Cancer Society Research Center recently published a study furthering their analysis of homologous recombination DNA repair machinery. The group previously reported on a growth factor, PSIP1, that enables DNA end resection. With GFP-transfected U2OS cells, the group investigated a structurally similar protein, hepatoma-derived growth factor-related protein 2 (HDGFRP2). The Celigo analyzed cell number and viability via fluorescent markers. The group reports that HDGRFP2 may help to repair silent genes that have been impaired or active genes inhibited by DNA damage. Read the full publication here.
Celigo evaluates a plant extract for glioblastomoa multiforme treatment
At the Canary Center at Stanford for Early Cancer Detection, investigators studied how AshwaMAX (a steroidal lactone from a winter cherry plant, Withania somnifera, extract) might work as an oral treatment for those with the highly aggressive cancer glioblastoma multiforme (GBM). A heterogeneous disease, non-specific therapies for GBM have proven largely ineffective. Two patient-derived GBM lines (GBM2, GBM39) and one GBM cell line were cultured to create neurospheres that were then exposed to various concentrations of AshwaMAX. Celigo measured cell proliferation and cell death via Trypan Blue staining. AshwaMAX inhibited the neurospheres at nanomolar concentrations. After additional work in vivo, [...]
Cellometer investigates new treatment paradigm for advanced endometrial cancer
University of North Carolina researchers investigated different techniques for inhibiting the catalytic activity of protein hTERT – a marker of advanced stage endometrial cancer. Endometrial cancer cell lines ECC-1 and Ishikawa were exposed to either siRNA or a small molecule pharmacological inhibitor BIBR1532, in addition to the drug paclitaxel, to see whether inhibiting hTERT provided additional efficacy against these cancer cells. The Cellometer, in combination with propidium iodide and Annexin-V FITC, calculated apoptosis in the various treatment conditions. The hTERT inhibition plus paclitaxel did prove synergistic, reducing cell growth and invasion more than paclitaxel alone. Furthermore, BIBR1532 antagonized cell invasion [...]
Celigo Advances studies in T Cell Therapy as a pediatric CHOP patient defeats her recurrent leukemia with immunotherapy
Emily Whitehead, cancer survivor, holding Nexcelom cell counting sheep. Thanks to the lifesaving T cell therapy clinical trial at Children’s Hospital of Philadelphia, Emily Whitehead is now two years cancer free. Diagnosed with acute lymphoblastic leukemia (ALL) right after her 5th birthday, doctors discovered that Emily’s leukemia was particularly resistant to chemotherapy, as are roughly 15% of the total number of ALL cases. After two recurrences of the disease, Emily’s parents enrolled her in a clinical trial for CTL019, an experimental therapeutic using a patient’s own reprogrammed T cells to eliminate the cancer cells. Now 9 years old, [...]
Cellometer Vision provides new method for measuring cytotoxic potential in Natural Killer Cells
The MD Anderson Cancer Center worked in collaboration with Nexcelom to create a new method by which to measure the cytotoxic potential of natural killer (NK) cells. The traditional non-radioactive method, calcein release, is subject to variation, with differing dynamic ranges depending on tumor type. The Cellometer Vision and calcein, in combination with K562, 721.221, and Jurkat cells, were used to develop a novel, image cytometry-based assay to ascertain NK cytotoxicity. Using fluorescent intensity gating to ignore dimmer cells and apoptotic bodies, image cytometry provided a way to measure tumor cell lysis in a specific manner with the same experimental [...]
Ignyta tests Celigo against Cell Titer-Glo for cell proliferation
Here's a great example of how the Celigo image cytometer is able to perform common experiments while saving time and money! Ignyta, Inc. was looking for a new way to perform reagent-free proliferation analyses with suspension cells. This new method had to produce results which correlated well to their current method, Cell Titer-Glo®. Nexcelom and Ignyta partnered to perform a head-to-head cell proliferation comparison between Celigo® and Cell Titer-Glo. Using four suspension cell types (Ba/F3 parental cell line, Ba/F3 expressing an oncogenic gene, oncogenic gene mutant A and B), Ignyta plated all cells at a concentration of 5,000 cells/well in [...]